IGFBP3 and metabolic disease: For example, targeting SERPING1 to modulate complement activation could be beneficial in treating autoimmune conditions, while IGFBP3 could be explored as a therapeutic agent in cancer and metabolic disorders due to its regulatory influence on cell growth and survival.31